Effect of Spirnolactone in heart failure
Phase 3
- Conditions
- Heart failure.congestive heart failure
- Registration Number
- IRCT2015010520563N1
- Lead Sponsor
- Ahwaz Jundishapur University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Inclusion critria: patient with systolic heart failure ? symptomatic ? EF<40
EXCLUSION critria:Known contraindications for spironolactone or prior documented intolerance to an aldosterone receptor antagonist ?Significant laboratory abnormalities (potassium = 5.1 mmol) ? Mental disorders suspected to interact with study outcome ?Pregnant women ? Significant renal dysfunction (creatinine . 1.8 mg/dL) ? Significant hypotension (blood pressure , 90 mmHg systolic and/or ,50 mmHg diastolic ? CRT or ICD
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ejection Fraction. Timepoint: At start of study and 6 month later. Method of measurement: Percent.;Functional capacity. Timepoint: At start of study and 6 month later. Method of measurement: 6 minute walk test { meter}.;Qulity of life. Timepoint: At start of study and 6 month later. Method of measurement: Minesutta Qulity of life qustionare{ score}.
- Secondary Outcome Measures
Name Time Method Cr. Timepoint: at start. after 3 month. after 6 month. Method of measurement: mg/dL.;Potasium. Timepoint: at start. after 3 month. after 6 month. Method of measurement: mg/dL.;Hypotansion. Timepoint: at start. after 3 month. after 6 month. Method of measurement: mmHG.